Adverum is a clinical-stage gene therapy company targeting unmet medical need in ocular and rare diseases. We develop gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Our core capabilities include clinical development, novel vector discovery, and in-house manufacturing expertise, specifically in scalable process development, assay development, and current Good Manufacturing Practices (cGMP) quality control. Our team has extensive clinical development experience and is laser-focused on advancing novel gene therapies for patients. Source
No articles found.
Sangamo Therapeutics, Inc. is focused on translating ground-breaking science into ...
Sangamo Therapeutics, Inc. is focused on transl...
Scopus BioPharma develops small molecule therapeutics leveraging world-class exper...
Scopus BioPharma develops small molecule therap...
PLUS THERAPEUTICS is a clinical-stage pharmaceutical company focused on making a p...
PLUS THERAPEUTICS is a clinical-stage pharmaceu...
Avalon GloboCare Corp. (NASDAQ: AVCO) is a global intelligent biotech developer an...
Avalon GloboCare Corp. (NASDAQ: AVCO) is a glob...
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on deve...
Aptevo Therapeutics Inc. is a clinical-stage bi...
Nemaura Medical (NASDAQ:NMRD) is a medical technology company which has developed ...
Nemaura Medical (NASDAQ:NMRD) is a medical tech...
bluebird bio is pioneering gene therapy with purpose. From our Cambridge, Mass., h...
bluebird bio is pioneering gene therapy with pu...
Join the National Investor Network and get the latest information with your interests in mind.